Abacus Global Management posts record origination, gains in 2025

Abacus Global purchased 1,310 life insurance policies in 2025, reporting record origination and transaction activity as it expanded its life settlements footprint. The firm said it set new benchmarks across key portfolio metrics, indicating stronger origination platform and consistent deal flow that should support asset growth and revenue potential for ABX.

Analysis

Scale in life settlements is a multiplier, not a linear benefit: once origination fixed costs and due-diligence infrastructure are built, each incremental policy meaningfully lowers marginal acquisition cost and shortens payback on capital. That creates a two-step re-rating path — first a near-term uplift to realized IRR from tighter origination economics, then a larger multi-quarter rerating if the firm can package policies into fee-bearing securitizations that convert illiquid holdings into recurring-deposit-like revenues.

Key tail risks center on underwriting (longevity) and funding. A 1-2 year miss in median mortality timing or a 150–300bp sustained rise in short-term borrowing costs materially compresses IRRs on purchased policies and raises break-evens for new originations; conversely, improving access to low-cost warehouse financing or prime ABS placements can expand equity returns by 300–800bps across a multi-year horizon.

Competitive dynamics: incumbents with proprietary origination channels and in-house actuarial models gain a durable advantage — third-party aggregators and boutique originators will face margin pressure and consolidation. Regulators and litigants are a persistent overhang; a regulatory tightening in a single large state or a precedent-setting wrongful-sale case could reset pricing assumptions industry-wide and temporarily freeze ABS markets, creating a 3–9 month liquidity shock.

Key Decisions for Investors

• Long ABL (1–2yr): accumulate on any <10% post-release pullback. Thesis: scale + path to securitization can drive a 25–40% realized upside if management converts incremental volume into fee-bearing AUM; downside: regulatory or mortality shocks. Position size: starter 1–2% NAV, add into weakness; hard stop -20%.
• Pair trade (6–12 months): Long ABL / Short LNC (Lincoln National). Rationale: ABL re-rating from private-market fee conversion vs legacy life insurers whose earnings suffer if secondary market growth accelerates; target relative outperformance 20–30% with limited market beta. Hedge: delta-neutral with 0.6x notional short to match market exposure.
• Credit/private allocation (3–18 months): deploy into senior tranches of life-settlement securitizations or warehouse debt at 8–12% gross yields via private channels (prefer bilateral warehouse exposures with covenant protection). Risk: tranche mispricing on mortality; mitigate with stress tests assuming +2yrs longevity and 300bp rate moves.
• Event hedge (0–12 months): buy ABL downside protection (puts or paid put spread) sized to cover 50–75% of notional exposure ahead of potential regulatory rulings or ABS deal announcements. Cost-capped protection preserves upside while limiting tail loss from litigation/regulatory shocks.